Mirum Pharmaceuticals vs Travere Therapeutics
Mirum Pharmaceuticals reported revenue of $521 million in fiscal 2025, about the same as Travere Therapeutics' $491 million in fiscal 2025. Mirum Pharmaceuticals' revenue grew 54.7% in its latest year, and Travere Therapeutics' grew 110.5%. Mirum Pharmaceuticals had an operating margin of -4.2%, against -12.8% at Travere Therapeutics.
Side by side
| Mirum Pharmaceuticals | Travere Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $521M | $491M |
| Revenue growth | 54.7% | 110.5% |
| Revenue growth a year, last 5 years | — | 19.9% |
| Gross margin | — | 97.9% |
| Operating margin | −4.2% | −12.8% |
| Net margin | −4.5% | −5.2% |
| Free cash flow | $55M | — |
| Free cash flow margin | 10.5% | — |
| Return on capital | −7.1% | — |
| Net debt to EBITDA | −34.9x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 5.6% | 13.1% |
| Last close | $93.99 | $50.65 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $9.0 million, sold $42.9 million | sold $95.9 million |
| Piotroski F-score | 5 of 8 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Mirum PharmaceuticalsTravere Therapeutics
Operating margin
Percent of revenue
Mirum PharmaceuticalsTravere Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Mirum PharmaceuticalsTravere Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Mirum Pharmaceuticals and Travere Therapeutics pages.